The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Does timing of Immune checkpoint inhibitors (ICIs) administration in first line Metastatic Renal Cell Carcinoma (mRCC) have impact in survival outcomes?
 
Javier Molina-Cerrillo
Consulting or Advisory Role - Advanced Accelerator Applications; BMS; Eisai; Ipsen; Janssen; Pfizer; Sanofi
Speakers' Bureau - BMS; Ipsen; Pfizer
Research Funding - Ipsen; Pfizer
Travel, Accommodations, Expenses - Ipsen
 
Ignacio Ortego
No Relationships to Disclose
 
Alvaro Pinto
Consulting or Advisory Role - Astellas Pharma; Bayer; Bristol-Myers Squibb; Ipsen; Janssen Oncology; MSD Oncology; Novartis; Pfizer; Pierre Fabre; Roche; Sanofi/Aventis
Research Funding - Bristol-Myers Squibb; Bristol-Myers Squibb; Pfizer
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Janssen; Pfizer; Roche
 
Teresa Alonso-Gordoa
Consulting or Advisory Role - Advanced Accelerator Applications/Novartis; Astellas Pharma; Bayer; Bristol-Myers Squibb; Eisai; Ipsen; Janssen-Cilag; Lilly; Merck; Pfizer; Roche; Sanofi
Research Funding - Ipsen; Pfizer; Roche
Travel, Accommodations, Expenses - Ipsen; Pfizer
 
Francesco Massari
No Relationships to Disclose
 
Gaetano Aurilio
No Relationships to Disclose
 
Sebastiano Buti
No Relationships to Disclose
 
Matteo Santoni
No Relationships to Disclose
 
Enrique Grande
Honoraria - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Eisai; Eusa Pharma; EUSA Pharma; IPSEN; Janssen-Cilag; Lilly; MSD; Novartis; Pfizer; Roche
Consulting or Advisory Role - Bristol-Myers Squibb; Ipsen; MSD; Pfizer; Roche; Roche
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Ipsen (Inst); Lexicon (Inst); Molecular Templates (Inst); Pfizer (Inst); Roche
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Ipsen; Janssen-Cilag; Pfizer; Roche/Genentech